The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

CDDF Multi-Stakeholder Workshop

Measurable Residual Disease (MRD) and Circulating Tumour nucleotides (ct DNA)

25 – 26 April 2022, Hybrid Workshop

Presentations

SESSION 1: STATE OF THE ART AND NEW TECHNOLOGY

MRD concepts, methods and application – Bruno Paiva (Universidad de Navarra, ES)

Established and Novel ctDNA Methodology – Dominic Rothwell (CRUK Manchester Institute Cancer Biomarker Centre, UK)

ctDNA and MRD, an academic point of view – Marie Morfouace (EORTC, BE)

Current Status and Clinical Application of Circulating Tumour DNA (ctDNA) and its Future Role in Clinical Practice – Jürgen Gschwend (Technical University Munich, DE)

SESSION 2: COLLABORATION - PATHWAY TO INNOVATION

MPAACT Consortium to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development – Reshma Patel (Johnson & Johnson, UK)

Exploring the use of ctDNA for Monitoring Treatment Response: The Friends of Cancer Research ctMoniTR Project – Christopher Hourigan (National Institutes of Health, USA)

The Foundation for the National Institutes of Health (FNIH) initiative on AML MRD – Jeff Allen (Friends of Cancer Research, USA)

SESSION 3: REGULATORY PERSPECTIVES

Summary of Regulatory Uses of MRD and ctDNA – Nicole Gormley (FDA, USA)

SESSION 4: IMPORTANT VIEWPOINTS

European In Vitro Diagnostic Regulations – Industry perspective – Claudia Popp (Roche, CH)

The value of MRD and ctDNA in cancer drug development, from the patient group perspective – Hans Scheurer (MPE, NL)

HTA perspective – Carole Longson (NICE, UK)

MRD in Solid Cancers: perspective of industry – Darren Hodgson (AstraZeneca, UK)